Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback